Pharmacogenomic Testing in Psychiatry: Ready for Primetime?

Area of Science:

• Psychiatry
• Genetics
• Clinical Pharmacology

Background:

• Pharmacogenomic testing is increasingly used in clinical psychiatry for treatment decisions.
• Despite growing interest, robust evidence for its efficacy is limited.
• Clinicians need a primer on the biological basis, benefits, and pitfalls of this testing.

Purpose of the Study:

• To provide clinicians with an understanding of pharmacogenomic testing in psychiatry.
• To review the biological underpinnings, evidence, and clinical decision-making challenges.
• To discuss current relevance, patient communication, and future research needs.

Main Methods:

• Review of existing evidence on pharmacogenomic testing in psychiatry.
• Use of clinical vignettes to illustrate concepts.
• Discussion of analytical validity, clinical validity, and utility.

Main Results:

• Pharmacogenomic testing demonstrates strong analytical validity.
• Clinical validity is modest, and evidence supporting clinical utility is minimal.
• Current evidence does not support its use in leading initial treatment plans.

Conclusions:

• More rigorous double-blinded randomized controlled trials are necessary.
• Pharmacogenomic testing may serve an adjunct role but should not lead initial psychiatric treatment.
• Further research is crucial to establish clinical utility and guide evidence-based practice.